Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 2Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms 1Pain 1Oligodendroglioma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Glioma 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

Temozolomide 45Radiotherapy 16Carboplatin 15Irinotecan 12Carmustine 12Bevacizumab 12Filgrastim 10Vincristine 9Surgical Procedures, Operative 9Magnetic Resonance Spectroscopy 9Procarbazine 7Peripheral Blood Stem Cell Transplantation 6Imatinib Mesylate 6Erlotinib Hydrochloride 6temsirolimus 5sargramostim 5O(6)-benzylguanine 5Lomustine 5Flucytosine 5Etoposide 5Thiotepa 4Sirolimus 4Cyclophosphamide 4aldesleukin 3Thalidomide 3Surveys and Questionnaires 3Sunitinib 3Radiotherapy, Intensity-Modulated 3Radiation 3Polymerase Chain Reaction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Oligodendroglioma × tandutinib × Clear all
NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡